Due to the increasing prevalence of antibiotic-resistant bacteria, an increasing number of patients will suffer from antibiotic-resistant infections. Unfortunately, medical providers do not currently have rapid diagnostic tests that will help them know if a patient will respond to a specific antibiotic treatment option. This forces medical providers to treat infections first, then wait several days for standard laboratory test results that determine which antibiotics were appropriate for treatment.
Impact: Increased risk of treatment failure and worsening infection, increased healthcare-associated costs, and increasing prevalence of antibiotic resistance.
BioAmp is developing point-of-care diagnostic tests that provide medical personnel with actionable results to direct the appropriate use of antibiotics. BioAmp utilizes a patented amplification technology to enable detection of low-abundance resistance biomarkers directly in patient samples.